• Mi Re-Unir
    Búsqueda Avanzada
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Ver ítem 
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem

    Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

    Autor: 
    Simon, Iris
    ;
    Perales, Sonia
    ;
    Casado-Medina, Laura
    ;
    Rodríguez-Martínez, Alba
    ;
    Garrido-Navas, M. Carmen
    ;
    Puche-Sanz, Ignacio
    ;
    Diaz-Mochon, Juan J.
    ;
    Alaminos, Clara
    ;
    Lupiañez, Pablo
    ;
    Lorente, José Antonio
    ;
    Serrano, M. José
    ;
    Real, Pedro J.
    Fecha: 
    2021
    Palabra clave: 
    abiraterone; androgen receptor; AR‐V7; AR‐V9; Castration resistant prostate cancer; cross‐resistance; enzalutamide; novel hormonal agents; transcriptional regulation; Scopus; WOS(2)
    Revista / editorial: 
    Cancers
    Tipo de Ítem: 
    Articulo Revista Indexada
    URI: 
    https://reunir.unir.net/handle/123456789/11606
    DOI: 
    https://doi.org/10.3390/cancers13061483
    Dirección web: 
    https://www.mdpi.com/2072-6694/13/6/1483
    Open Access
    Resumen:
    Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status (CRPC) is commonly developed. The expression of androgen receptor (AR) alternative splicing isoforms (AR‐V7 and AR‐V9) has been associated to CRPC. However, resistance mechanisms to novel NHAs are not yet well understood. Androgen‐dependent PCa cell lines were used to generate resistant models to ADT only or in combination with Abiraterone and/or Enzalutamide (concomitant models). Functional and genetic analyses were performed for each resistance model by real‐time cell monitoring assays, flow cytometry and RT‐qPCR. In androgen‐dependent PCa cells, the administration of Abiraterone and/or Enzalutamide as first‐line treatment involved a critical inhibition of AR activity associated with a significant cell growth inhibition. Genetic analyses on ADT‐resistant PCa cell lines showed that the CRPC phenotype was accompanied by overexpression of AR full‐length and AR target genes, but not necessarily AR‐V7 and/or AR‐V9 isoforms. These ADT resistant cell lines showed higher proliferation rates, migration and invasion abilities. Importantly, ADT resistance induced cross‐resistance to Abiraterone and/or Enzalutamide. Similarly, concomitant models possessed an elevated expression of AR full‐length and proliferation rates and acquired cross‐resistance to its alternative NHA as second‐ line treatment.
    Mostrar el registro completo del ítem
    Este ítem aparece en la(s) siguiente(s) colección(es)
    • Artículos Científicos WOS y SCOPUS

    Estadísticas de uso

    Año
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    Vistas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    38
    60
    51
    66
    69
    Descargas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    Ítems relacionados

    Mostrando ítems relacionados por Título, autor o materia.

    • The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers 

      Garrido-Navas, M. Carmen ; García-Díaz, Abel; Molina-Vallejo, María Pilar; González-Martínez, Coral; Alcaide Lucena, Miriam; Cañas-García, Inés; Bayarri, Clara; Delgado, Juan Ramón; González, Encarna; Lorente, José Antonio; Serrano, M. José (Cancers, 11/2020)
      Being minimally invasive and thus allowing repeated measures over time, liquid biopsies are taking over traditional solid biopsies in certain circumstances such as those for unreachable tumors, very early stages or treatment ...
    • I Congreso Español de Videojuegos 2022 

      González Calero, Pedro Antonio; Gómez Martín, Marco Antonio; Gómez Martín, Pedro Pablo; Gutiérrez Manjón, Sergio; Gutiérrez Sánchez, Pablo; Peinado, Federico; Sánchez-Ruiz Granados, Antonio; Barbancho, Isabel; Blanco Bueno, Carlos; Botella Nicolás, Ana María; Chover, Miguel; Díaz Álvarez, Josefa; Echeverría, Jorge; Fernández Leiva, Antonio J.; Fernández Ruiz, Marta; Gallego-Durán, Francisco; García Sánchez, Pablo; Gutiérrez Vela, Francisco L; Lara-Cabrera, Raúl; León, Carlos; Moreno, Jorge L.; Lozano Muñoz, Alejandro; Mayor, Jesús; Medina Medina, Nuria; Mejías-Climent, Laura; Mora, Antonio M; Munarriz, Jaime; Patow, Gustavo A.; Sagredo-Olivenza, Ismael; Salinas, María-José; Sanchez I. Peris, Francesc Josep; Sánchez-Ruiz, Antonio A; Shliakhovchuk, Elena; Tejada, Jesus (CEUR Workshop Proceedings, 2022)
      {Resumen no disponible]
    • Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study 

      Rodríguez-Toscano, Elisa; Alloza, Clara; Fraguas, David; Durán-Cutilla, Manuel; Roldán, Laura; Sánchez-Gutiérrez, Teresa; López-Montoya, Gonzalo; Parellada, Mara; Moreno, Carmen; Gayer-Anderson, Charlotte; E Jongsma, Hannah; Di Forti, Marta; Quattrone, Diego; Velthorst, Eva; de Haan, Lieuwe; Selten, Jean-Paul; Szöke, Andrei; Llorca, Pierre-Michel; Tortelli, Andrea; Bobes, Julio; Bernardo, Miguel; Sanjuán, Julio; Santos, José Luis; Arrojo, Manuel; Tarricone, Ilaria; Berardi, Domenico; Ruggeri, Mirella; Lasalvia, Antonio; Ferraro, Laura; La Cascia, Caterina; La Barbera, Daniele; Rossi Menezes, Paulo; Del-Ben, Cristina Marta; EU-GEI WP2 Group; Rutten, Bart P.; van Os, Jim; Jones, Peter B.; M. Murray, Robin; B. Kirkbride, James; Morgan, Craig; Díaz-Caneja, Covadonga M.; Arango, Celso (Schizophrenia Bulletin, 2023)
      Background: Use of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe ...

    Mi cuenta

    AccederRegistrar

    ¿necesitas ayuda?

    Manual de UsuarioContacto: reunir@unir.net

    Listar

    todo Re-UnirComunidades y coleccionesPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de accesoEsta colecciónPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de acceso






    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja
     
    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja